Safety aspects of 36 months of administration of long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals

European Journal of Endocrinology

Volumn 161, Issue 5, 2009, Pages 795-798

  Jacobeit, J W ^a   Gooren, L J ^b   Schulte, H M ^a  

^a ENDOKRINOLOGIKUM HAMBURG   (Germany)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TESTOSTERONE; TESTOSTERONE UNDECANOATE; TRIACYLGLYCEROL; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DRUG DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; TESTOSTERONE DERIVATIVE;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG SAFETY; FEMALE; FEMALE TO MALE TRANSSEXUAL; HEMATOCRIT; HUMAN; HYPOGONADISM; PRIORITY JOURNAL; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; VIRILIZATION; BLOOD; INTRAMUSCULAR DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; TRANSSEXUALISM;

ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; CHOLESTEROL; FEMALE; HEMATOCRIT; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INJECTIONS, INTRAMUSCULAR; MIDDLE AGED; STATISTICS, NONPARAMETRIC; TESTOSTERONE; TESTOSTERONE CONGENERS; TRANSSEXUALISM; TRIGLYCERIDES; YOUNG ADULT;

EID: 70449708079     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-09-0412     Document Type: Article

References (27)

1. Gooren L. The endocrinology of transsexualism: a review and commentary. Psychoneuroendocrinology 1990 15 3-14.
2. Gooren LJ, Giltay EJ & Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. Journal of Clinical Endocrinology and Metabolism 2008 93 19-25.
3. Gooren LJ & Giltay EJ. Review of studies of androgen treatment of female-to-male transsexuals: effects and risks of administration of androgens to females. Journal of Sexual Medicine 2008 5 765-776.
4. Nieschlag E. Testosterone treatment comes of age: new options for hypogonadal men. Clinical Endocrinology 2006 65 275-281. (Pubitemid 44244915)
5. Saad F, Kamischke A, Yassin A, Zitzmann M, Schubert M, Jockenhel F, Behre HM, Gooren L & Nieschlag E. More than eight years' hands-on experience with the novel long-acting parenteral testosterone undecanoate. Asian Journal of Andrology 2007 9 291-297. (Pubitemid 47097283)
6. Jacobeit JW, Gooren LJ & Schulte HM. Long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals. Journal of Sexual Medicine 2007 4 1479-1484.
7. Mueller A, Kiesewetter F, Binder H, Beckmann MW & Dittrich R. Long-term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-to-male transsexuals. Journal of Clinical Endocrinology and Metabolism 2007 92 3470-3475. (Pubitemid 47435322)
8. Meriggiola MC, Armillotta F, Costantino A, Altieri P, Saad F, Kalhorn T, Perrone AM, Ghi T, Pelusi C & Pelusi G. Effects of testosterone undecanoate administered alone or in combination with letrozole or dutasteride in female to male transsexuals. Journal of Sexual Medicine 2008 5 2442-2453.
9. Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, Gooren LJ, Meyer WJ III, Spack NP, Tangpricha V & Montori VM. Endocrine treatment of transsexual persons. An endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2009 94 3132-3154.
10. Harle L, Basaria S & Dobs AS. Nebido: a long-acting injectable testosterone for the treatment of male hypogonadism. Expert Opinion on Pharmacotherapy 2005 6 1751-1759. (Pubitemid 41167682)
11. Schubert M, Minnemann T, Hubler D, Rouskova D, Christoph A, Oettel M, Ernst M, Mellinger U, Krone W & Jockenhovel F. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. Journal of Clinical Endocrinology and Metabolism 2004 89 5429-5434. (Pubitemid 39518421)
12. Mueller A & Gooren L. Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones. European Journal of Endocrinology 2008 159 197-202.
13. Spinder T, Spijkstra JJ, van den Tweel JG, Burger CW, van Kessel H, Hompes PG & Gooren LJ. The effects of long term testosterone administration on pulsatile luteinizing hormone secretion and on ovarian histology in eugonadal female to male transsexual subjects. Journal of Clinical Endocrinology and Metabolism 1989 69 151-157. (Pubitemid 19172440)
14. Spinder T, Spijkstra JJ, Gooren LJ, Hompes PG & van Kessel H. Effects of long-term testosterone administration on gonadotropin secretion in agonadal female to male transsexuals compared with hypogonadal and normal women. Journal of Clinical Endocrinology and Metabolism 1989 68 200-207. (Pubitemid 19028746)
15. Behre HM,Wang C, Handelsman DJ & Nieschlag E. Pharmacology of testosterone preparations. In Testosterone, Action, Deficiency, Substitution, pp 405-444. Eds E Nieschlag & HM Behre, New York: Cambridge University Press, 2004.
16. Drinka PJ, Jochen AL, Cuisinier M, Bloom R, Rudman I & Rudman D. Polycythemia as a complication of testosterone replacement therapy in nursing home men with low testosterone levels. Journal of the American Geriatrics Society 1995 43 899-901.
17. Kaufman JM & Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocrine Reviews 2005 26 833-876. (Pubitemid 41428540)
18. Jockenhovel F, Vogel E, Reinhardt W & Reinwein D. Effects of various modes of androgen substitution therapy on erythropoiesis. European Journal of Medical Research 1997 2 293-298.
19. Nieschlag E, Buchter D, Von Eckardstein S, Abshagen K, Simoni M & Behre HM. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men. Clinical Endocrinology 1999 51 757-763. (Pubitemid 30050826)
20. Behre HM, Abshagen K, Oettel M, Hubler D & Nieschlag E. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. European Journal of Endocrinology 1999 140 414-419. (Pubitemid 29254007)
21. von Eckardstein S & Nieschlag E. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. Journal of Andrology 2002 23 419-425. (Pubitemid 34297331)
22. Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE & Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. Journal of Clinical Endocrinology and Metabolism 1999 84 3469-3478. (Pubitemid 30645193)
23. Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB & Bhasin S. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. Journal of Clinical Endocrinology and Metabolism 2008 93 914-919.
24. Elbers JM, Giltay EJ, Teerlink T, Scheffer PG, Asscheman H, Seidell JC & Gooren LJ. Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects. Clinical Endocrinology 2003 58 562-571. (Pubitemid 36566798)
25. Giltay EJ & Gooren LJ. Effects of sex steroid deprivation/ administration on hair growth and skin sebum production in transsexual males and females. Journal of Clinical Endocrinology and Metabolism 2000 85 2913-2921.
26. Berra M, Armillotta F, D'Emidio L, Costantino A, Martorana G, Pelusi G & Meriggiola MC. Testosterone decreases adiponectin levels in female to male transsexuals. Asian Journal of Andrology 2006 8 725-729. (Pubitemid 44869622)
27. Moore E, Wisniewski A & Dobs A. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. Journal of Clinical Endocrinology and Metabolism 2003 88 3467-3473. (Pubitemid 37034478)